Pfizer's CEO warns that China's meticulously executed national plan for pharma—improving regulators, strengthening IP, and funding science—is a disruptive force. Operating at half the cost and three times the speed, China is on track to lead in multiple areas of drug discovery within 1-2 years.

Unlike previous technologies, ChatGPT’s launch created immediate, widespread pressure on biopharma executives. Prompted by their boards and even families, they recognized the potential to leapfrog years of development, rapidly elevating AI on the corporate agenda despite concerns about data privacy and IP.

Using AI for incremental efficiency gains (10% thinking) is becoming table stakes. True competitive advantage lies in 10X thinking: using AI to fundamentally reimagine your business model, services, and market approach. Companies that only optimize will be outmaneuvered by those that transform.

Pfizer's CEO argues the US is wasting resources trying to slow China's progress in pharma. He advocates shifting 80% of the effort to becoming better and faster domestically. This involves transforming US companies with technology and pushing for systemic changes in regulation, funding, and drug pricing.

The idea that AI leads to job cuts misses the competitive dynamic. Since all companies have access to AI, efficiency gains will be reinvested to out-compete rivals, not just pocketed as profit. This escalates competition, turning AI adoption into a strategic imperative for survival and growth.

Albert Bourla identifies Chinese pharmaceutical companies as a paradigm-shifting threat, not an incremental one. He quantifies their advantage as operating with "half the cost and three times the speed," demanding a fundamental transformation of Western pharma companies within five years to remain competitive.

The pharmaceutical industry risks repeating Kodak's failure of inventing but ignoring a disruptive technology. For Kodak, it was digital photography; for pharma, it's AI. The industry possesses vast amounts of data (the new 'film'), but the real danger lies in failing to embrace the AI-driven intelligence layer that can interpret and act on it.

Long-term competitive advantage will belong not to firms with the best algorithms, but to those that build the most intelligent organizations *around* AI. The key is developing the ability to absorb, direct, and compound AI's power in service of coherent strategic goals.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.